Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
Chen V, Umemura S, Han Y, Raman R, Tucker R, Chahine J, Kim IK, Schatz C, Zitzmann-Kolbe S, Sommer A, Onda M, Lee T, He Y, Giaccone G.
Chen V, et al. Among authors: onda m.
Br J Cancer. 2022 Mar;126(5):754-763. doi: 10.1038/s41416-021-01658-6. Epub 2021 Dec 7.
Br J Cancer. 2022.
PMID: 34876673
Free PMC article.